Protocol Ledger

NCT07224321 · Phase II · RECRUITING

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

Interventional Phase II clinical trial protocol NCT07224321 sponsored by Mannkind in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-04 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07224321
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07224321
Protocol FieldVerified Registry Value
NCT IdentifierNCT07224321
Consolidated Lead SponsorMannkind
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2026-02-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI